Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation
Future Pharmacology · 23.06.2026 · 6 (3) · 34
DOI: 10.3390/futurepharmacol6030034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 23.06.2026. Verfasst von Gabriella de Souza Gomes Ribeiro und 3 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAPES, FAPESP.
Abstract (Originalsprache)
Background/Objectives: In this study, we present an analysis of ayahuasca, a psychedelic preparation containing N,N-dimethyltryptamine (DMT) and β-carbolines, such as harmine (HRM), a reversible monoamine oxidase A (MAO-A) inhibitor that enables the oral bioavailability of DMT. CYP2D6 is a highly polymorphic enzyme associated with interindividual variability in drug exposure, but its influence on the pharmacokinetics of ayahuasca alkaloids remains poorly understood.
Methods
Using physiologically based pharmacokinetic (PBPK) modeling, we simulated scenarios for poor (PM), normal (NM), and ultra-rapid (UM) metabolizers by adjusting CYP2D6 enzyme expression for each phenotype.
Results
PMs showed increased systemic exposure to DMT (AUC +53.3%; Cmax +40.5%) and HRM (AUC +30.6%; Cmax +22.8%), while UMs exhibited reduced exposure to both compounds.
Conclusions
These findings highlight the significant impact of CYP2D6 polymorphisms on the pharmacokinetics of DMT and HRM, reinforcing the value of PBPK modeling for predicting interindividual variability and potential clinical risks.
Förderung
- CAPES
- FAPESP
Zitieren
APA
Ribeiro, G. D. S. G., Annaert, P., Martins, F. S., & Marcourakis, T. (2026). Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation. Future Pharmacology, 6(3), 34. https://doi.org/10.3390/futurepharmacol6030034
Vancouver
Ribeiro GDSG, Annaert P, Martins FS, Marcourakis T. Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation. Future Pharmacology. 2026;6(3):34. doi:10.3390/futurepharmacol6030034
BibTeX
@article{Ribeiro2026,
author = {Ribeiro, Gabriella de Souza Gomes and Annaert, Pieter and Martins, Frederico Severino and Marcourakis, Tania},
title = {Impact of CYP2D6 Polymorphisms on the Pharmacokinetics of N,N-Dimethyltryptamine and Harmine via PBPK Modeling and Simulation},
journal = {Future Pharmacology},
year = {2026},
volume = {6},
number = {3},
pages = {34},
doi = {10.3390/futurepharmacol6030034}
}
EUVIMED